Phase I Study of BEBT-209 in Women With Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE1
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
- Status
- COMPLETED
- Phase
- PHASE2
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
- Status
- RECRUITING
- Phase
- PHASE2
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of AVZO-021 in Patients With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
- Status
- COMPLETED
- Phase
- PHASE4
VS-6766+Abema+Fulv in Met HR+/HER- BC
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2